Industry ownership intelligence

Medical Devices insider conviction

Executive and director activity assessed across 83 companies for breadth, transaction quality, clustering, freshness, and directional conviction.

Market dashboardHealthcare sectorCompany signalsFiling ledgerData API
48/100

Balanced insider tape

90/100 confidence
Level
Industry
Evidence window
Latest 90 days
Named insiders
642
Latest evidence
7 Aug 2026

Capital positioning read

Balanced insider tape

Acquisition and disposal evidence is mixed after low-information compensation and derivative activity is separated out.

Wait for clearer clustering

Evidence in favour

  • 126 distinct acquisition events survive duplicate and security-type controls.
  • Participation spans 642 named insiders rather than one filing source.
  • The latest qualifying evidence is fresh, dated 07 Aug 2026.

Decision risks

  • Qualifying disposal events outnumber acquisitions, although disposals receive a lower directional weight.
Conviction48Balanced insider tape
Confidence90Deep evidence
Controlled events489directional common-share events
Company breadth83represented companies
Acquisition value$26.8Mnormalized amount
Disposal value$270.7Mnormalized amount

Flow regime

Twelve-week filing pressure

Shows the cadence and balance of the full filing tape.

15825 May
30901 Jun
16008 Jun
15715 Jun
7922 Jun
11129 Jun
7006 Jul
4213 Jul
3420 Jul
8227 Jul
5303 Aug
010 Aug
AcquisitionsDisposalsScore 48 · Confidence 90

Relative positioning

Industry peer map

Current score with confidence.

Pharmaceutical RetailersConviction accumulation7216 confidence Medical DistributionAccumulation bias6667 confidence Drug Manufacturers - GeneralAccumulation bias5794 confidence BiotechnologyBalanced insider tape5291 confidence Medical DevicesBalanced insider tape4890 confidence Diagnostics & ResearchDistribution bias3895 confidence Medical Care FacilitiesDistribution bias3693 confidence Health Information ServicesDistribution bias3691 confidence Medical Instruments & SuppliesDistribution bias3691 confidence Drug Manufacturers - Specialty & GenericDistribution bias3594 confidence Healthcare PlansDistribution bias3492 confidence

Directional balance

Controlled event mix

25.8%acquisition
Acquisition events
126
Disposal events
363
Net value
-$243.9M

Evidence quality

What the filings represent

Common equity1021
Equity compensation301
Options and derivatives231
Other securities10

Decision makers

Role participation

Director886
Other executive252
CEO and chair145
Finance leadership115
Other or unspecified112
Large holder53

Quality controls

Evidence usability

Normalized values
34%
Priced common share
33%
Named insiders
642
Controlled events
489

Auditable evidence

Latest Medical Devices filings

Showing 1021 to 1050 of 1563.

STESTERIS plc
ZANGERLE, JOHN ADAMSr. VP, Gen Counsel, and Sec.
DisposalCommon equity
$51.8KDirectional evidence
NVCRNovocure Ltd
HILLEMAN, JERYL LDirector
DisposalCommon equity
$46.4KDirectional evidence
NVCRNovocure Ltd
HUNG, DAVIDDirector
DisposalCommon equity
$46.4KDirectional evidence
NVCRNovocure Ltd
LEUNG, GABRIELDirector
DisposalCommon equity
$46.4KDirectional evidence
NVCRNovocure Ltd
OCEAN, ALLYSON JDirector
DisposalCommon equity
$46.4KDirectional evidence
NVCRNovocure Ltd
SCANNELL, TIMOTHY JDirector
DisposalCommon equity
$46.4KDirectional evidence
NVCRNovocure Ltd
STAFFORD, KRISTINDirector
DisposalCommon equity
$46.4KDirectional evidence
NVCRNovocure Ltd
VERNON, W ANTHONYDirector
DisposalCommon equity
$46.4KDirectional evidence
STESTERIS plc
MADSEN, JULIASr. VP and GM, Life Sciences
DisposalCommon equity
$26.6KDirectional evidence
MASS908 Devices Inc
AWM, INVESTMENT COMPANY, INC.10% Owner
DisposalOther securities
$22.4KContext evidence
LUNGPulmonx Corp
FRENCH, GLENDON E. IIIDirector, President and CEO
DisposalCommon equity
$21.2KDirectional evidence
RCELAvita Medical Ltd
WOODY, JOSEPH FRALINDirector
AcquisitionCommon equity
$21.0KDirectional evidence
RCELAvita Medical Ltd
WOODY, JOSEPH FRALINDirector
AcquisitionCommon equity
$20.9KDirectional evidence
STESTERIS plc
MAJORS, CARY LSVP and President, Healthcare
DisposalCommon equity
$14.1KDirectional evidence
STESTERIS plc
BURTON, KAREN LSr. Vice Pres., CFO
DisposalCommon equity
$13.8KDirectional evidence
STESTERIS plc
KOHLER, KENNETH ESVP & GM, AST
DisposalCommon equity
$13.8KDirectional evidence
STESTERIS plc
TAMARO, RENATOV.P. & Corporate Treasurer
DisposalCommon equity
$8.6KDirectional evidence
BFLYButterfly Network Inc
CAEZZA, NICHOLASDeputy General Counsel
DisposalCommon equity
$7.8KDirectional evidence
CNMDCONMED Corporation
BRONSON, DAVID M.Director
AcquisitionEquity compensation
Not reportedContext evidence
CNMDCONMED Corporation
COUNCIL, LAVERNE HDirector
AcquisitionEquity compensation
Not reportedContext evidence
CNMDCONMED Corporation
FARKAS, CHARLESDirector
AcquisitionEquity compensation
Not reportedContext evidence
CNMDCONMED Corporation
KAYE, MARKDirector
AcquisitionEquity compensation
Not reportedContext evidence
CNMDCONMED Corporation
KELDERMAN, KIMDirector
AcquisitionEquity compensation
Not reportedContext evidence
CNMDCONMED Corporation
SCHWARZENTRAUB, BARBARA JDirector
AcquisitionEquity compensation
Not reportedContext evidence
CVRXCVRx Inc
BALLINGER, KEVIN J.Director
AcquisitionOptions and derivatives
Not reportedContext evidence
CVRXCVRx Inc
BALLINGER, KEVIN J.Director
AcquisitionCommon equity
Not reportedContext evidence
CVRXCVRx Inc
DALE, MICHAEL DDirector
AcquisitionCommon equity
Not reportedContext evidence
CVRXCVRx Inc
DALE, MICHAEL DDirector
AcquisitionOptions and derivatives
Not reportedContext evidence
CVRXCVRx Inc
HILL,, MITCH C.Director
AcquisitionCommon equity
Not reportedContext evidence
CVRXCVRx Inc
HILL,, MITCH C.Director
AcquisitionOptions and derivatives
Not reportedContext evidence

Group-level method

Breadth before headline value

Company breadth

A sector or industry score must be supported across companies. One very large filing cannot manufacture broad conviction.

Economic duplicates

Matching company, date, side, security class, share count, and value records are consolidated for the directional calculation.

Evidence hierarchy

Priced common-share activity determines direction. Compensation and derivative records are mapped separately so ownership mechanics remain visible.

Positioning use

The score identifies where insider alignment merits research or where disposal concentration needs review. Price, trend, valuation, and portfolio risk still decide positioning.

Independent market research for education. This classification is not investment advice, a recommendation, a forecast, or an execution instruction.

Evidence context